AIM IP specialist Tekcapital to sell or float all four portfolio companies 'within 2 years'. Watch the full video here

Less Ads, More Data, More Tools Register for FREE

Oxford's Brazil vaccine trial to continue after volunteer dies -university

Wed, 21st Oct 2020 18:19

LONDON, Oct 21 (Reuters) - The University of Oxford's
Brazilian trial of its vaccine candidate will continue after the
death of a volunteer, the university said on Wednesday, adding
an independent review had revealed no safety concerns.

"Following careful assessment of this case in Brazil, there
have been no concerns about safety of the clinical trial and the
independent review in addition to the Brazilian regulator have
recommended that the trial should continue," a spokesman for the
university said in a statement.

The vaccine has been licenced to AstraZeneca.

(Reporting by Alistair Smout
Editing by Chris Reese)

Related Shares

More News

UK to give under 40s alternative to AstraZeneca vaccine

(Sharecast News) - The UK government decided on Friday to offer people under 40 an alternative to the AstraZeneca Covid-19 vaccine, reported Bloomberg.

7 May 21 09:49

All under-40s to be offered alternative to AstraZeneca vaccine

All under-40s to be offered alternative to AstraZeneca vaccine

7 May 21 08:49

AstraZeneca reports positive results in Phase 3 lung cancer drug trial

AstraZeneca reports positive results in Phase 3 lung cancer drug trial

7 May 21 08:32

AstraZeneca's Imfinzi demonstrates benefit in combination with antibody

(Sharecast News) - AstraZeneca reported on Friday that 'Imfinzi' and tremelimumab with chemotherapy demonstrated an overall survival benefit in the 'POSEIDON' trial for first-line stage four non-small cell lung cancer, making it the first phase 3 trial to demonstrate an overall survival benefit with tremelimumab.

7 May 21 07:42

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.